ROIV
Price
$11.16
Change
+$0.27 (+2.48%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
7.93B
31 days until earnings call
VRNA
Price
$51.89
Change
-$1.75 (-3.26%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
4.39B
41 days until earnings call
Ad is loading...

ROIV vs VRNA

Header iconROIV vs VRNA Comparison
Open Charts ROIV vs VRNABanner chart's image
Roivant Sciences
Price$11.16
Change+$0.27 (+2.48%)
Volume$87.21K
Capitalization7.93B
Verona Pharma
Price$51.89
Change-$1.75 (-3.26%)
Volume$38.72K
Capitalization4.39B
ROIV vs VRNA Comparison Chart
Loading...
ROIV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ROIV vs. VRNA commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ROIV is a Hold and VRNA is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (ROIV: $10.89 vs. VRNA: $53.64)
Brand notoriety: ROIV and VRNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ROIV: 72% vs. VRNA: 185%
Market capitalization -- ROIV: $7.93B vs. VRNA: $4.39B
ROIV [@Biotechnology] is valued at $7.93B. VRNA’s [@Biotechnology] market capitalization is $4.39B. The market cap for tickers in the [@Biotechnology] industry ranges from $370.67B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ROIV’s FA Score shows that 1 FA rating(s) are green whileVRNA’s FA Score has 1 green FA rating(s).

  • ROIV’s FA Score: 1 green, 4 red.
  • VRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, ROIV is a better buy in the long-term than VRNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ROIV’s TA Score shows that 4 TA indicator(s) are bullish while VRNA’s TA Score has 3 bullish TA indicator(s).

  • ROIV’s TA Score: 4 bullish, 5 bearish.
  • VRNA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ROIV is a better buy in the short-term than VRNA.

Price Growth

ROIV (@Biotechnology) experienced а -1.18% price change this week, while VRNA (@Biotechnology) price change was +16.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.05%. For the same industry, the average monthly price growth was +3.04%, and the average quarterly price growth was -1.59%.

Reported Earning Dates

ROIV is expected to report earnings on Jun 25, 2025.

VRNA is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ROIV($7.93B) has a higher market cap than VRNA($4.39B). VRNA YTD gains are higher at: 15.504 vs. ROIV (-7.946). ROIV has higher annual earnings (EBITDA): 4.15B vs. VRNA (-136.9M). ROIV has more cash in the bank: 5.39B vs. VRNA (336M). ROIV has less debt than VRNA: ROIV (52.7M) vs VRNA (122M). ROIV has higher revenues than VRNA: ROIV (129M) vs VRNA (5.62M).
ROIVVRNAROIV / VRNA
Capitalization7.93B4.39B181%
EBITDA4.15B-136.9M-3,032%
Gain YTD-7.94615.504-51%
P/E Ratio1.97N/A-
Revenue129M5.62M2,294%
Total Cash5.39B336M1,603%
Total Debt52.7M122M43%
FUNDAMENTALS RATINGS
VRNA: Fundamental Ratings
VRNA
OUTLOOK RATING
1..100
85
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
PROFIT vs RISK RATING
1..100
5
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ROIVVRNA
RSI
ODDS (%)
Bullish Trend 4 days ago
72%
Bearish Trend 4 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
58%
Bearish Trend 4 days ago
79%
Momentum
ODDS (%)
Bearish Trend 4 days ago
64%
Bullish Trend 4 days ago
82%
MACD
ODDS (%)
N/A
Bearish Trend 4 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
70%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
68%
Bullish Trend 4 days ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 8 days ago
73%
Bearish Trend 8 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
74%
Aroon
ODDS (%)
Bearish Trend 4 days ago
71%
Bullish Trend 4 days ago
82%
View a ticker or compare two or three
Ad is loading...
ROIV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY591.64-1.14
-0.19%
SPDR® S&P 500® ETF Trust
BTC.X99756.910000-747.585940
-0.74%
Bitcoin cryptocurrency
GME27.72-0.24
-0.86%
GameStop Corp
TSLA413.82-14.40
-3.36%
Tesla
AAPL228.26-9.61
-4.04%
Apple

ROIV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ROIV has been loosely correlated with IMVT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ROIV jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ROIV
1D Price
Change %
ROIV100%
-1.63%
IMVT - ROIV
50%
Loosely correlated
-2.46%
ALDX - ROIV
41%
Loosely correlated
-4.88%
DYN - ROIV
40%
Loosely correlated
-4.95%
STOK - ROIV
40%
Loosely correlated
-0.32%
ACLX - ROIV
40%
Loosely correlated
-0.74%
More

VRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRNA has been loosely correlated with AKBA. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if VRNA jumps, then AKBA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRNA
1D Price
Change %
VRNA100%
+6.62%
AKBA - VRNA
36%
Loosely correlated
-0.52%
TRDA - VRNA
34%
Loosely correlated
+2.37%
RNA - VRNA
33%
Poorly correlated
+1.51%
ARQT - VRNA
32%
Poorly correlated
-1.22%
ROIV - VRNA
32%
Poorly correlated
-1.63%
More